Showing 4981-4990 of 5760 results for "".
- DermTech Adds Dr. Harold Rabinovitz to Scientific Advisory Boardhttps://practicaldermatology.com/news/dermtech-adds-harold-rabinovitz-to-scientific-advisory-board/2457982/DermTech, Inc., appointed Harold Rabinovitz, MD to its Scientific Advisory Board. Dr. Rabinovitz is a Board Certified Dermatologist and a voluntary Clinical Professor of Dermatology at University of Miami School of Medicine. He is world-renown for his work in dermoscopy and confocal microscopy.</
- Novan Plans to Complete Development of SB204 Acne Candidate via Third Party Funding and Executionhttps://practicaldermatology.com/news/novan-plans-to-complete-development-of-sb204-acne-candidate-via-third-party-funding-and-execution/2457981/Novan, Inc., has agreed in principle to a business structure that would enable further development and advancement of SB204 for the treatment of acne vulgaris via third party financing and third party execution of one additional Phase 3 pivotal trial that is required before the filing of a New Dr
- Save the Dates: eRelevance Launches National Marketing Education Tour for Aesthetic Healthcare Practiceshttps://practicaldermatology.com/news/erelevance-launches-national-marketing-education-tour-for-aesthetic-healthcare-practices/2457983/eRelevance Corporation announced the expansion of its popular marketing education workshops to more cities nationwide. The workshops help aesthetic healthcare providers understand the significant opportunity in marketing to their existing patient
- New from Jergens: Nourishing Honey Dry Skin Moisturizerhttps://practicaldermatology.com/news/new-from-jergens-nourishing-honey-dry-skin-moisturizer/2457984/Jergens is launching their new Nourishing Honey Dry Skin Moisturizer. Formulated with antioxidant-packed Orange Blossom Honey, which is known to contain potent antibacterial and anti-inflammatory properties, the new Jergens® Nouri
- Dermatomyositis Breakthrough? Drug reduces disease burden in patients with skin-predominant DMhttps://practicaldermatology.com/news/dermatomyositis-breakthrough-drug-reduces-disease-burden-in-patients-with-skin-predominant-dm/2457990/A new treatment for dermatomyositis (DM) may reduce the severity of the disease in patients whose DM was resistant to other therapies. As part of a randomized, double-blind study conducted at the Perelman School of Medicine at the University of Pennsyl
- Prospective Cosmetic Surgery Patients Often In The Dark About Financing Optionshttps://practicaldermatology.com/news/prospective-cosmetic-surgery-patients-in-the-dark-about-financing-options/2457994/Fully 76 percent of prospective patients are unaware of financing options for cosmetic procedures, yet almost two-thirds of them would be more likely to book if they were aware that financing was a viable option, according to a survey by
- Philips Rolls Out New Three-In-One Skincare Devicehttps://practicaldermatology.com/news/philips-rolls-out-new-three-in-one-skincare-device/2457997/Philips is introducing Philips VisaPure Advanced, a new three-in-one facial skincare tool. The new device works to remove impurities that have accumulated in pores resulting in lesser appearance of enlarged or clogged pores and blackheads, which c
- Menlo Therapeutics Expands Management Teamhttps://practicaldermatology.com/news/menlo-therapeutics-expands-management-team/2458006/Menlo Therapeutics Inc., a late stage biopharmaceutical company, is developing a neurokinin 1 (NK‐1) receptor antagonist (serlopitant) for the treatment of pruritus associated with various underlying conditions, and for the treatment of refractory chronic cough. The company, which continues to ad
- PruGen Pharmaceuticals Takes Action to Aid Hurricane Relief Effortshttps://practicaldermatology.com/news/prugen-pharmaceuticals-takes-action-to-aid-hurricane-relief-efforts/2458007/In the wake of several devastating and destructive hurricanes in the continental US and Puerto Rico, PruGen Pharmaceuticals is helping to those in need. The PruGen Foundation, a nonprofit organization founded by PruGen Pharmaceuticals and focused on philanthropic
- FDA Approves Stelara for Treatment of Adolescents with Moderate To Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-stelara-for-treatment-of-adolescents-with-moderate-to-severe-plaque-psoriasis/2458010/The FDA approved an expanded indication for Janssen Biotech, Inc.'s Stelara (ustekinumab) for the treatment of adolescents (12 years of age or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Today's approval marks a significant mile